Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain

Prostatype Genomics (”Prostatype Genomics” or ”the Company”) announces that the retrospective multicentre study in Spain with the Company’s gene test Prostatype®, which includes 126 patients with prostate cancer at seven hospitals and is coordinated by the Spanish National Urology Association, has now been completed with strong positive results. The final results show that the treatment plan could have been modified for 39% of the patients if Prostatype® had been used as a decision basis at the time of diagnosis. Prostatype® was launched in Spain in 2023, and Prostatype Genomics now see good conditions to facilitate a broader use of the product and thus increase sales in this market.

In addition to showing that usage of Prostatype® at the time of diagnosis would have prompted reclassification of 39% of the patients, the study also showed the following:

- Prostatype® can predict progression, i.e. predict which of the patients that need curative treatment immediately upon diagnosis and who are therefore not suitable for active monitoring.

- Prostatype® confirms the cases in which it may be appropriate to postpone curative treatment for some men with low-risk prostate cancer.

The results from the study will, as previously communicated, be presented at the annual meeting of the Spanish National Urology Association in Santander in April 2024.

“The strong positive final results in this Spanish multicentre study, which is in line with previously announced interim results, provides further scientific support for the great benefits of using Prostatype® as a decision basis when selecting treatment type for patients with diagnosed prostate cancer. We therefore expect that several Spanish urologists, that have shown great interest but previously waited for the time being, now will begin to use the test in their clinical practices,” says Prostatype Genomics’ CEO Fredrik Rickman.

Based on the very positive results, the Spanish National Urology Association and Prostatype Genomics have decided to continue the study and make it more comprehensive. Completion is expected in 2024.

Prostatype Genomics has identified Spain as one of its focus markets in Europe. The number of new cases of prostate cancer in the country amounts to over 32,000 per year, and there is a strong awareness among both urologists and the Spanish National Urology Association that an improved risk classification of diagnosed prostate cancer can lead to greatly improved quality of life for many patients, as well as shorter healthcare queues and significant cost savings.

For further information about Prostatype Genomics, please contact:

Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB

Telephone: +46 (0) 73 049 77 01

Email: [email protected]

About Prostatype Genomics AB

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB. The Company’s Certified Advisor is Carnegie Investmentbank AB.